Propranolol in the therapeutic strategy of infantile laryngotracheal hemangioma: A preliminary retrospective study of French experience
Nicolas Leboulanger(Hôpital Necker-Enfants Malades), Françoise Denoyelle(Hôpital Necker-Enfants Malades), L. Carrabin(Hôpital Necker-Enfants Malades), N. Teissier(Sorbonne Paris Cité), T. Van Den Abbeele(Inserm), T. Mom(Institut National de Recherche pour l'Agriculture, l'Alimentation et l'Environnement), Jean‐Paul Marie(Hôpital Charles-Nicolle), Jean‐Michel Triglia(Hôpital de la Timone), P. Fayoux(Université de Lille), Patrick Froehlich(Hôpital Edouard Herriot), M. Mondain, Rémy Marianowski(Centre Hospitalier Régional Universitaire de Brest), Vincent Couloigner(Hôpital Necker-Enfants Malades), Éréa-Noël Garabédian(Inserm), Sonia Ayari(Hôpital Edouard Herriot), Gilles Roger(Inserm), R. Nicollas(Hôpital de la Timone), Amanda Cox(Sorbonne Université), E. Lescanne(Centre Hospitalier Universitaire de Tours)
Cited by 110
Related Papers
GJB2 Mutations and Degree of Hearing Loss: A Multicenter Study
|The American Journal of Human Genetics|2005|558
IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H)
|Journal of Clinical Investigation|2009|299
Role of Propranolol in the therapeutic strategy of infantile laryngotracheal hemangioma
|International Journal of Pediatric Otorhinolaryngology|2009|235
Cytomegalovirus-Induced Brain Malformations in Fetuses
|Journal of Neuropathology & Experimental Neurology|2014|162
Langerhans cell histiocytosis: therapeutic strategy and outcome in a 30‐year nationwide cohort of 1478 patients under 18 years of age
|British Journal of Haematology|2016|130